Open AccessMechanisms of chemotherapy resistance in ovarian cancer
Author(s) -
Mylena Ortiz,
Emma Wabel,
Kerry Mitchell,
Sachi Horibata
Publication year - 2022
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.147
Subject(s) - ovarian cancer , olaparib , bevacizumab , medicine , paclitaxel , chemotherapy , oncology , vascular endothelial growth factor , drug resistance , cancer research , pharmacology , cancer , poly adp ribose polymerase , polymerase , vegf receptors , biology , dna , microbiology and biotechnology , genetics
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.